Physician profile
Daniel Bennett
NPI 1255355467
$3,547.60
in general payments reported to CMS, 2019-2025
22 companies · $145 in 2025
The $145 reported for 2025 was less than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $687 · 2020: $14.27 · 2021: $367 · 2022: $192 · 2023: $76.32 · 2024: $2,066 · 2025: $145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,410 · Food and Beverage: $877.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,410.18 |
| Food and Beverage | $876.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Si-Bone, INC. | $1,704.62 | 2024 | |
| Amniox Medical, INC. | $526.57 | 2019 | |
| Boston Scientific Corporation | $320.66 | 2020-2025 | Intracept, Wavewriter Alpha Prime 16, General - Therapies |
| Amgen INC. | $300.79 | 2021-2022 | |
| Abbvie INC. | $179.44 | 2021-2024 | Qulipta |
| Nalu Medical, INC. | $149.96 | 2024 | Nalu Neurostimulation System |
| Antares Pharma, INC. | $50.00 | 2022 | |
| Avanos Medical | $41.56 | 2019 | |
| Nevro Corp. | $40.61 | 2019 | |
| Idorsia Pharmaceuticals US INC | $32.64 | 2022-2023 | Quviviq |
| Allergan, INC. | $29.28 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $25.20 | 2019 | |
| Globus Medical, INC. | $23.08 | 2024 | Allocate |
| Acella Pharmaceuticals, LLC | $16.84 | 2023 | NP Thyroid 60 |
| Eisai INC. | $15.14 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $14.64 | 2019 | |
| Biotronik INC. | $13.14 | 2022 | |
| Vertos Medical, INC. | $13.04 | 2023 | Mild Device Kit |
| Pfizer INC. | $13.03 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $13.00 | 2019 | |
| Kaleo, INC. | $12.79 | 2019 | |
| Redhill Biopharma INC. | $11.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Bennett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.